Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cryoport, Inc.CYRX · Entity 5125 | Director | June 05, 2026 | June 09, 2026 |
| PRA Health Sciences, Inc.PRAH · Entity 15912 | Executive VP & CFO | January 16, 2018 | January 18, 2018 |
| WATERS CORP /DE/WAT · Entity 3080 | Director | February 25, 2026 | February 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cryoport, Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,099 |
Reported balance
After 2026-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 10,350 · Balance 68,099 F1: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis. |
| Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $15.70 · Expires 2033-06-05 | Direct | 16,077 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 16,077 · Balance 16,077 F2: 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis.
F2: 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026.
PRA Health Sciences, Inc.
Report date January 16, 2018 · Filed January 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-01-16 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2018-01-16 · Exercise / conversion · Acquired 67,000 · Balance 67,000 Row 2 · 2018-01-16 · Sale · Disposed 64,405 · Balance 2,595 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $89.54 to $90.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Row 3 · 2018-01-16 · Sale · Disposed 2,595 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $90.54 to $90.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.73 · Expires 2023-12-20 | Direct | 39,931 |
Reported balance
After 2018-01-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-01-16 · Exercise / conversion · Disposed 39,374 · Balance 39,931 F4: The options vested on September 23, 2017. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.73 · Expires 2023-12-20 | Direct | 117,669 |
Reported balance
After 2018-01-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-01-16 · Exercise / conversion · Disposed 27,626 · Balance 117,669 F5: The options vested on March 2, 2016 upon satisfaction of certain performance criteria. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $89.54 to $90.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $90.54 to $90.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4: The options vested on September 23, 2017.
F5: The options vested on March 2, 2016 upon satisfaction of certain performance criteria.
WATERS CORP /DE/
Report date February 25, 2026 · Filed February 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,899 |
Reported balance
After 2026-02-25 transaction · row 1
1 source rowRow 1 · 2026-02-25 · Grant · Acquired 23 · Balance 2,899 F1: Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $319.44 · Expires 2036-02-25 | Direct | 57 |
Reported balance
After 2026-02-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-25 · Grant · Acquired 57 · Balance 57 F2: All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027.
F2: All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2019 Filed Jan 4, 2019 18:34 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 599 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-001129 · form4.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 891 F1 · shares: Grant of shares of common stock subject to restrictions that lapse January 2, 2020. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 20:34 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantStock Option (Right to Buy) · Derivative | 1,249 | $0.00 Strike: $188.26 | $0.00 |
DisclosureSEC source: 0001127602-18-026805 · form4.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,249 Underlying: Common Stock · 1,249 shares Expires 2028-09-04 F2 · derivative.exercise_date: Options fully vest on September 4, 2019. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 20:34 UTC | WATERS CORP /DE/ WAT · Entity 3080 | GrantCommon Stock | 292 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-026805 · form4.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292 F1 · shares: Grant of shares of common stock subject to restrictions that lapse September 4, 2019. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 16:36 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,626 | $0.00 Strike: $11.73 | $0.00 |
DisclosureSEC source: 0001104659-18-002870 · a4.xml · derivative · entry 5 BADDOUR LINDA · CIK 0001181151 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,669 Underlying: Common Stock · 27,626 shares Expires 2023-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options vested on March 2, 2016 upon satisfaction of certain performance criteria. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 16:36 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | Exercise / conversionStock Option (Right to Buy) · Derivative | 39,374 | $0.00 Strike: $11.73 | $0.00 |
DisclosureSEC source: 0001104659-18-002870 · a4.xml · derivative · entry 4 BADDOUR LINDA · CIK 0001181151 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,931 Underlying: Common Stock · 39,374 shares Expires 2023-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vested on September 23, 2017. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 16:36 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | SaleCommon Stock | 2,595 | $90.56 | $235,003.20 |
DisclosureSEC source: 0001104659-18-002870 · a4.xml · nonDerivative · entry 3 BADDOUR LINDA · CIK 0001181151 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $90.54 to $90.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 16:36 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | SaleCommon Stock | 64,405 | $90.26 | $5,813,195.30 |
DisclosureSEC source: 0001104659-18-002870 · a4.xml · nonDerivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,595 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $89.54 to $90.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 16:36 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | Exercise / conversionCommon Stock | 67,000 | $11.73 | $785,910.00 |
DisclosureSEC source: 0001104659-18-002870 · a4.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 16:06 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $75.81 | $0.00 |
DisclosureSEC source: 0001104659-17-054928 · a4.xml · derivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-08-29 F1 · derivative.exercise_date: The options vest as follows: (a) 20% on each of August 29, 2018 and August 29, 2019, and (b) 30% on each of August 29, 2020 and August 29, 2021, subject to the holder's continued service through each applicable vesting date. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 16:01 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | SaleCommon Stock | 100,000 | $74.85 | $7,485,000.00 |
DisclosureSEC source: 0001104659-17-052247 · a4.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This amount represents the secondary price per share of common stock, par value $0.01 per share, of PRA Health Sciences, Inc. received by the reporting person in an underwritten secondary block trade. Read SEC document |
| August 08, 2017 Filed Aug 10, 2017 16:08 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | Exercise / conversionStock Option (Right to Buy) · Derivative | 52,965 | $0.00 Strike: $11.73 | $0.00 |
DisclosureSEC source: 0001104659-17-051049 · a4.xml · derivative · entry 3 BADDOUR LINDA · CIK 0001181151 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,295 Underlying: Common Stock · 52,965 shares Expires 2023-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested on March 2, 2016 upon satisfaction of certain performance criteria. Read SEC document |
| August 08, 2017 Filed Aug 10, 2017 16:08 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | Exercise / conversionStock Option (Right to Buy) · Derivative | 47,035 | $0.00 Strike: $11.73 | $0.00 |
DisclosureSEC source: 0001104659-17-051049 · a4.xml · derivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,305 Underlying: Common Stock · 47,035 shares Expires 2023-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 7,383 of the options vested on September 23, 2015; 39,652 of the options vested on September 23, 2016. The remaining options will vest in equal installments on September 23, 2017 and September 23, 2018. Read SEC document |
| August 08, 2017 Filed Aug 10, 2017 16:08 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | Exercise / conversionCommon Stock | 100,000 | $11.73 | $1,173,000.00 |
DisclosureSEC source: 0001104659-17-051049 · a4.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 16:02 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | Exercise / conversionStock Option (Right to Buy) · Derivative | 71,921 | $0.00 Strike: $11.73 | $0.00 |
DisclosureSEC source: 0001104659-17-024510 · a4.xml · derivative · entry 7 BADDOUR LINDA · CIK 0001181151 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,340 Underlying: Common Stock · 71,921 shares Expires 2023-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 39,652 of the options vested on September 23, 2014; 32,269 of the options vested on September 23, 2015. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 16:02 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,343 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001104659-17-024510 · a4.xml · derivative · entry 6 BADDOUR LINDA · CIK 0001181151 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,343 shares Expires 2022-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vested on September 23, 2013. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 16:02 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | Exercise / conversionStock Option (Right to Buy) · Derivative | 108,129 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001104659-17-024510 · a4.xml · derivative · entry 5 BADDOUR LINDA · CIK 0001181151 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108,129 shares Expires 2017-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vested on September 23, 2013. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 16:02 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | SaleCommon Stock | 71,921 | $63.59 | $4,573,456.39 |
DisclosureSEC source: 0001104659-17-024510 · a4.xml · nonDerivative · entry 4 BADDOUR LINDA · CIK 0001181151 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $63.34 to $63.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 16:02 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | Exercise / conversionCommon Stock | 71,921 | $11.73 | $843,633.33 |
DisclosureSEC source: 0001104659-17-024510 · a4.xml · nonDerivative · entry 3 BADDOUR LINDA · CIK 0001181151 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 16:02 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | SaleCommon Stock | 124,472 | $63.59 | $7,915,174.48 |
DisclosureSEC source: 0001104659-17-024510 · a4.xml · nonDerivative · entry 2 BADDOUR LINDA · CIK 0001181151 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $63.34 to $63.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 16:02 UTC | PRA Health Sciences, Inc. PRAH · Entity 15912 | Exercise / conversionCommon Stock | 124,472 | $2.94 | $365,947.68 |
DisclosureSEC source: 0001104659-17-024510 · a4.xml · nonDerivative · entry 1 BADDOUR LINDA · CIK 0001181151 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.